Morningstar has issued a BUY recommendation on CRISPR Therapeutics AG (NASDAQ: CRSP), underscoring the stock’s significant undervaluation and robust long-term prospects, in its latest research repo

In its latest equity analyst report, Morningstar maintains a “Hold” (fairly valued) recommendation on FedEx Corp (NYSE: FDX), reflecting a nuanced view of the company’s current valuation, operation

In its latest analyst report, Morningstar maintains a "Buy" recommendation on Tripadvisor Incorporated (TRIP), highlighting the company’s undervalued status, strategic opportunities, and persistent

Shopify continues to validate its position as a dominant player in the e-commerce infrastructure space, with Morningstar reiterating a Buy rating and a fair value estimate of $120 per share, repres

Sanofi, the French pharmaceutical heavyweight, has earned a reaffirmed BUY rating from Morningstar as of May 2025.

Cloudflare, the mid-cap technology firm synonymous with distributed network security and web performance, received an upgraded fair value estimate of $130 per share from Morningstar, reflecting gro